Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines
Aleksandr V Ponomarev1, Irina Zh Shubina1, Zinaida A Sokolova1
1N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Abstract:
Numerous studies have shown that antitumor vaccines based on synthetic peptides are safe and can induce both CD8+ and CD4+ tumor-specific T cell responses. However, clinical results are still scarce, and such approach to antitumor treatment has not gained a wide implication, yet. Recently, particular advances have been achieved due to tumor sequencing and the search for immunogenic neoantigens caused by mutations. One of the most important issues for peptide vaccines, along with the choice of optimal adjuvants and vaccination regimens, is the search for effective target antigens. Extensive studies of peptide vaccines, including those on murine models, are required to reveal the effective vaccine constructs. The review presents transplantable murine tumors with the detected peptides that showed antitumor efficacy as a vaccine compound.
Insights
Synthetic peptide antitumor vaccines are safe and induce T cell responses, but clinical success is limited. Research is ongoing to identify effective peptide vaccine targets using murine models.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Synthetic peptide-based antitumor vaccines demonstrate safety and elicit CD8+ and CD4+ T cell responses.
- Clinical efficacy of these vaccines remains limited, hindering widespread application.
- Advances in tumor sequencing and neoantigen discovery offer new avenues for vaccine development.
Purpose of the Study:
- To review transplantable murine tumor models with identified peptides.
- To highlight peptides that have shown antitumor efficacy as vaccine compounds.
- To underscore the importance of identifying effective target antigens for peptide vaccines.
Main Methods:
- Review of existing literature on synthetic peptide antitumor vaccines.
- Analysis of studies involving murine models and transplantable tumors.
- Identification of specific peptides demonstrating antitumor effects.
Main Results:
- Murine models provide valuable platforms for evaluating peptide vaccine constructs.
- Certain identified peptides within transplantable tumors have shown promise as vaccine components.
- The selection of optimal adjuvants, vaccination regimens, and target antigens is crucial.
Conclusions:
- Peptide vaccines hold potential for cancer treatment, but further research is essential.
- Murine models are critical for advancing the development of effective peptide vaccine strategies.
- Identifying potent tumor-specific antigens is key to improving clinical outcomes.
